All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a healthcare professional. If you are a patient or carer, please visit the Lymphoma Coalition.

  TRANSLATE

The Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

The Lymphoma Hub
Brought to you by Scientific Education Support

The Lymphoma Hub is an independent medical education platform, sponsored by Roche, AbbVie, BeOne, Miltenyi Biomedicine, Thermo Fisher, Nurix Therapeutics and Caribou Biosciences and supported through independent educational grants from Incyte, Bristol Myers Squibb, Pfizer and Takeda Pharmaceuticals U.S.A., Inc. Funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.

View all

Now you can support HCPs in making informed decisions for their patients

Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.

Find out more

EHA-SWG 2017 | Rare Lymphomas: Immune Checkpoint Inhibitors

By Karl Kemp-O'Brien

Share:

Mar 22, 2017

On March 12th, at the EHA-SWG Rare Lymphomas Scientific Meeting 2017 in Barcelona, Spain, Marie José Kersten chaired a scientific session on ‘Fighting Lymphoma with T-cells’. The second presentation of this session was by Stephen Ansell, from the Mayo Clinic, Rochester, USA, on the topic of ‘Immune Checkpoint Inhibitors’. Below are the key highlights from this presentation:

  • Immune checkpoint inhibitors may relieve the immune suppression seen in the lymphoma
  • PD-L1 and PD-L2 expression is increased in lymphoma cells
Anti-PD1 drugs target and prevent suppressive PD-L1 and PD-L2 signaling from occurring in lymphoma Nivolumab and pembrolizumab have been shown to be effective in treating Hodgkin Lymphoma Phase II studies have also had positive results for nivolumab and pembrolizumab in classical HL
Lower responses were seen in phase I results of nivolumab in R/R B-cell lymphoma and T-cell lymphoma
Combining PD-1 blockade with CTLA-4 blockade via nivolumab and ipilimumab has been shown to be effective in HL (ORR = 74%), but less effective in B-cell NHL (ORR = 20%)
Together this indicates that combination therapy with immune checkpoint inhibitors is a promising treatment option for NHL and HL

References

Please indicate your level of agreement with the following statements:

The content was clear and easy to understand

The content addressed the learning objectives

The content was relevant to my practice

I will change my clinical practice as a result of this content

More about...

Checkpoint inhibitors

This content is accurate as of the date of publication and is not updated retrospectively. Please refer to the latest available evidence, guidelines, and relevant regulatory information when making clinical decisions.

Your opinion matters

When selecting the next therapy for patients with R/R MCL after BTKi progression, what is your most important consideration?

Newsletter

Subscribe to get the best content delivered to your inbox